Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Shares Outstanding (Weighted Average) (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 115.28% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 115.28% year-over-year, with the annual reading at $1.6 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $3.4 million at Neuphoria Therapeutics, up from $2.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $155.9 million in Q2 2022, with the low at $43938.7 in Q2 2023.
  • Average Shares Outstanding (Weighted Average) over 4 years is $21.0 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 99.97% in 2023, then surged 115.28% in 2025.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $155.9 million in 2022, then plummeted by 99.97% to $43938.7 in 2023, then skyrocketed by 3485.1% to $1.6 million in 2024, then skyrocketed by 115.28% to $3.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $3.4 million, $2.2 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.